COVID-19 Pneumonia

Infectious Diseases
8
Pipeline Programs
9
Companies
9
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
2
0
4
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
250%
Small Molecule
250%
+ 6 programs with unclassified modality

On Market (1)

Approved therapies currently available

GS
VEKLURYApproved
remdesivir
Gilead Sciences
SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC]intravenous2020

Competitive Landscape

8 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
1 program
1
1
RemdesivirPhase 3Small Molecule1 trial
Active Trials
NCT04409262Completed649Est. Mar 2021
CytoDyn
CytoDynVANCOUVER, WA
2 programs
2
LeronlimabPhase 3Monoclonal Antibody1 trial
LeronlimabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT04901676Suspended612Est. Feb 2023
NCT04901689Suspended316Est. Feb 2023
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
RemdesivirPhase 3Small Molecule
Avalo Therapeutics
1 program
1
CERC-002Phase 21 trial
Active Trials
NCT04412057CompletedEst. Jan 2021
Vera Therapeutics
Vera TherapeuticsBRISBANE, CA
1 program
1
NestaCell®Phase 21 trial
Active Trials
NCT04315987CompletedEst. Feb 2021
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
1
Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal CellsPhase 1/21 trial
Active Trials
NCT04461925UnknownEst. Dec 2021
Verona Pharma
Verona PharmaUK - London
2 programs
Not applicableN/A1 trial
Single passive leg movementN/A1 trial
Active Trials
NCT05097677Completed7,599Est. May 2024
NCT04625036CompletedEst. May 2021
Aytu BioPharma
Aytu BioPharmaDENVER, CO
1 program
UVA Light Emitting CatheterN/A1 trial
Active Trials
NCT05166915WithdrawnEst. Dec 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CytoDynLeronlimab
CytoDynLeronlimab
Gilead SciencesRemdesivir
Avalo TherapeuticsCERC-002
Vera TherapeuticsNestaCell®
City TherapeuticsPlacenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells
Aytu BioPharmaUVA Light Emitting Catheter
Verona PharmaNot applicable
Verona PharmaSingle passive leg movement

Clinical Trials (9)

Total enrollment: 9,176 patients across 9 trials

NCT04901689CytoDynLeronlimab

Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation

Start: Oct 2021Est. completion: Feb 2023316 patients
Phase 3Suspended
NCT04901676CytoDynLeronlimab

Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia

Start: Sep 2021Est. completion: Feb 2023612 patients
Phase 3Suspended
NCT04409262Gilead SciencesRemdesivir

A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia

Start: Jun 2020Est. completion: Mar 2021649 patients
Phase 3Completed
NCT04412057Avalo TherapeuticsCERC-002

Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury

Start: Jul 2020Est. completion: Jan 2021
Phase 2Completed
NCT04315987Vera TherapeuticsNestaCell®

NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia

Start: Jun 2020Est. completion: Feb 2021
Phase 2Completed
NCT04461925City TherapeuticsPlacenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells

Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs

Start: May 2020Est. completion: Dec 2021
Phase 1/2Unknown
NCT05166915Aytu BioPharmaUVA Light Emitting Catheter

Respiratory COVID-19: A Randomized, Sham-Controlled Study

Start: Oct 2022Est. completion: Dec 2022
N/AWithdrawn
NCT05097677Verona PharmaNot applicable

Follow-up of Covid-19 Long Term Sequelae

Start: Apr 2021Est. completion: May 20247,599 patients
N/ACompleted
NCT04625036Verona PharmaSingle passive leg movement

NO-mediated Vascular Function in Covid-19 Patient

Start: May 2020Est. completion: May 2021
N/ACompleted

Related Jobs in Infectious Diseases

Director, Program Management

Metaphore Biotechnologies
Somerville, MA USA
9h ago
$179K - $237K/yr

Consultor Técnico Vacinas Adulto (Brasília/DF)

GSK
BRA - Distrito Federal - Brasília
22h ago

Production Supervisor/First Line Leader

GSK
USA - North Carolina - Zebulon
22h ago

Community Engagement Account Manager - New Haven

GSK
USA - Connecticut - New Haven
22h ago

Scientist, Protein Purification

GSK
USA - Massachusetts - Cambridge
22h ago
$90K - $150K/yr

Scientist, Protein Biochemistry

GSK
USA - Massachusetts - Cambridge
22h ago
$90K - $150K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
9 companies competing in this space

Related Indications

HIV Infections(449)COVID-19(223)Hepatitis C(191)Influenza(173)HIV(138)HIV-1-infection(115)Hepatitis C, Chronic(94)Chronic Hepatitis B(93)Chronic Hepatitis C(91)Covid19(79)